Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.

The oncologist - 1 Sept 2021

Jiao Xiao-Dong, Liu Ke, Wu Ying, Zhou Xin-Cheng, Qin Bao-Dong, Ling Yan, Liu Jun, He Xi, Du Haiwei, Xiang Jianxing, Zang Yuan-Sheng

Abstract excerpt

The addition of trastuzumab to chemotherapy regimen is the standard of care for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer; however, most patients eventually acquire trastuzumab resistance. Although some resistance mechanisms to trastuzumab-based regimens have been proposed, further understanding is required for developing therapeutic strategies to overcome the resistance. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor, ErbB-2

Share to Stomach Neoplasms

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 33896090
DOI: 10.1002/onco.13799
PMCID: PMC8417865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.PMID 33896090Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.Semantic proximity Read ↗

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.Semantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer lineSemantic proximity Read ↗

Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.Semantic proximity Read ↗

A Novel Gene Mutation of PIK3R1EY451delinsD in Breast Cancer with the Resistance to HER2-targeted TherapySemantic proximity Read ↗

Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic DatabaseSemantic proximity Read ↗

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.Semantic proximity Read ↗

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.